Alpha Tau Medical (DRTS) vs Inhibrx Biosciences (INBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alpha Tau Medical (DRTS) has outperformed Inhibrx Biosciences (INBX) over the past year, gaining 245.0% versus a gain of 178.7%. Inhibrx Biosciences is the larger company by market cap ($1.35 billion vs $1.27 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRTS | INBX |
|---|---|---|
| Share price | $13.76 | $91.75 |
| Market cap | $1.27B | $1.35B |
| 1-day change | -3.44% | -1.72% |
| YTD return | +187.88% | +18.18% |
| 1-year return | +245.04% | +178.69% |
| 5-year return | +44.08% | — |
| EPS (TTM) | $-1.04 | $-8.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.79 | $155.29 |
| 52-week low | $3.43 | $28.16 |
| Distance from 52-week high | -12.86% | -40.92% |
| Analyst consensus | none | none |
| Avg. price target upside | +29.36% | +190.65% |
| Average volume | 566.95K | 291.93K |
| Shares outstanding | 92.48M | 14.72M |
| Employees | 121 | 109 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DRTS has outperformed INBX by 66.3 percentage points over the past year.
About Alpha Tau Medical
DRTS stock →Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
Health Care · Medical/Dental Instruments · 121 employees
About Inhibrx Biosciences
INBX stock →Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
DRTS vs INBX FAQ
Which is bigger, Alpha Tau Medical or Inhibrx Biosciences?
Inhibrx Biosciences (INBX) is larger, with a market capitalization of $1.35B compared with $1.27B for Alpha Tau Medical (DRTS).
Which stock has performed better over the past year, DRTS or INBX?
DRTS returned +245.04% over the past 12 months, compared with +178.69% for INBX (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Tau Medical and Inhibrx Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Alpha Tau Medical and Biotechnology: Biological Products (No Diagnostic Substances) for Inhibrx Biosciences.